Arcus Biosciences

RCUS · Nasdaq · United States

Share price · RCUS

$15.76-13.75 (-46.59%) 3M

close as of 2026-11-18 · 24h delayed · vol 2.0M (0.9x 30-day avg)

Loading chart…

Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento

Compare with peers →

Unusual price moves

Days when RCUS's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked

  1. 21 Oct 2026-19.6%
  2. 24 Sep 2026-5.0%
  3. 11 Sep 2026-6.0%
  4. 10 Sep 2026-8.2%
  5. 22 Jun 2026+12.0%
  6. 22 Apr 2026+8.6%
  7. 21 Apr 2026+7.8%
  8. 2 Mar 2026+17.5%
  9. 15 Jan 2026-11.3%
  10. 13 Jan 2026+6.8%

Share of unusual movement by asset

For each asset, the share of RCUS's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.

AssetEvent daysShare of unusual movement
Casdatifan
events and moves
5shown from 8 days
Assets with fewer than 8 event days, together—7%
Other company news (earnings, financing, releases naming no asset)—24%
Sessions with no dated event—69%

Assets

(4 total)
4Total Assets
0Approved
2Phase 3 / Filed
2Phase 1–2 / Early
4Diseases
Quick filter:
Showing 4 of 4 assets
Target & Modality
Phase 3
HIF-2alphaSmall molecule
Renal Cell Carcinoma
Clear Cell Renal Cell Carcinoma
Phase 3
CD73 (NT5E)Small molecule
Pancreatic Ductal Adenocarcinoma
Phase 1
CD39 (ENTPD1)Monoclonal antibody
Non-Small Cell Lung CancerGastric Cancer
Phase 1
AXLSmall molecule
Non-Small Cell Lung Cancer

Upcoming events

(3 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
December 2027 (1)
QuemliclustatPhase 2Advanced Non-Small Cell Lung Cancer
Est. primary completion 2027-12 · NCT05676931 · CT.gov ↗
What to watch
2028 (1)
April 2028 (1)
CasdatifanPhase 3Metastatic Clear Cell Renal Cell Carcinoma, Advanced Clear Cell Renal Cell Carcinoma
Est. primary completion 2028-04 · NCT07011719 · CT.gov ↗
What to watch
2030 (1)
November 2030 (1)
QuemliclustatPhase 3Metastatic Pancreatic Ductal Adenocarcinoma
Est. primary completion 2030-11-30 · NCT06608927 · CT.gov ↗
What to watch

See the full readout calendar ↗

Financial reports

Quarterly & interim (16)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q3$3.0M$117M$151M+ $479M short-term inv.$128M-$88M operating cash flowreport ↗
View 15 more
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2026-Q2$33M$113M$150M+ $552M short-term inv.$91M-$119M operating cash flowreport ↗
2026-Q1$7.0M$122M$201M+ $621M short-term inv.$128M-$138M operating cash flowreport ↗
2025-Q3$6.0M$141M$238M+ $593M short-term inv.$135M-$97M operating cash flowreport ↗
2025-Q2$8.0M$139M$248M+ $663M short-term inv.—-$133M operating cash flowreport ↗
2025-Q1$8.0M$122M$192M+ $805M short-term inv.$112M-$132M operating cash flowreport ↗
2024-Q3$48M$123M$201M+ $888M short-term inv.$92M$26M operating cash flowreport ↗
2024-Q2$39M$115M$156M+ $813M short-term inv.$93M-$94M operating cash flowreport ↗
2024-Q1$145M$109M$185M+ $810M short-term inv.$4.0M-$2.0M operating cash flowreport ↗
2023-Q3$32M$82M$184M+ $615M short-term inv.$71M-$63M operating cash flowreport ↗
2023-Q2$29M$84M$230M+ $700M short-term inv.$75M-$57M operating cash flowreport ↗
2023-Q1$25M$81M$238M+ $716M short-term inv.$80M-$98M operating cash flowreport ↗
2022-Q3$34M$77M$218M+ $831M short-term inv.$65M-$81M operating cash flowreport ↗
2022-Q2$27M$70M$273M+ $900M short-term inv.$67M-$65M operating cash flowreport ↗
2022-Q1$18M$61M$549M+ $665M short-term inv.$68M$654M operating cash flowreport ↗
2021-Q3$9.5M$71M$179M$78M-$54M operating cash flowreport ↗

Annual history (5 years)

PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2025-FY$247M$523M$1.0B$353Mreport ↗

For fiscal year 2025, Arcus Biosciences reported revenue of $247M, down 4.3% YoY, with R&D spend of $523M, up 16.7% YoY. Cash and equivalents stood at $1,000M. Net income or loss was not disclosed, and quarterly net burn was $353M.

No formal financial guidance was provided, but the company highlighted clinical progress: the Phase 3 PEAK-1 trial of casdatifan with cabozantinib is enrolling, a second Phase 3 casdatifan study in a TKI-free first-line regimen is targeted to begin by the end of 2026, and the Phase 3 PRISM-1 study completed enrollment in September 2025 with results expected in the first half of 2027. Arcus also disclosed a December 2025 announcement regarding its Phase 3 STAR-221 trial of domvanalimab, and a temporary pause in recruitment for the eVOLVE-RCC02 study after immune-mediated adverse events were observed.

View 4 more years
PeriodRevenueR&DCash & equiv.Net loss / qtrFiling
2024-FY$258M$448M$992M$282Mreport ↗
2023-FY$117M$340M$127M+ $632M short-term inv.$77M-$306M operating cash flowreport ↗
2022-FY$112M$288M$206M+ $803M short-term inv.$67M$438M operating cash flowreport ↗
2021-FY$383M$256M$148M+ $351M short-term inv.—-$256M operating cash flowreport ↗

Insider transactions

Open-market activity, trailing 12 months: 0 purchases ($0), 32 sales ($9.5M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.

Source
2026-08-21Azoy Alexander · Chief Accounting OfficerOption exercise2,827$15.44$44KForm 4
2026-08-21Azoy Alexander · Chief Accounting OfficerOpen-market sale2,827$30.00$85KForm 4
2026-08-21Azoy Alexander · Chief Accounting OfficerOption exercise (derivative)2,827——Form 4
2026-07-10Jaen Juan C. · PresidentOpen-market sale19,799$28.61$566KForm 4
2026-07-10Jaen Juan C. · PresidentOpen-market sale268$29.40$8KForm 4
2026-07-09Jaen Juan C. · PresidentOpen-market sale48,502$30.05$1.5MForm 4
2026-06-24Jaen Juan C. · PresidentOpen-market sale6,431$29.66$191KForm 4
2026-06-23Jaen Juan C. · PresidentOpen-market sale14,067$27.69$389KForm 4

Institutional holders

From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 210 reporting institutions held 119.1M shares ($2.6B, 82.7% of shares outstanding).

#InstitutionSharesValue
1GILEAD SCIENCES, INC.31,424,760$678.8M
2BlackRock, Inc.15,226,475$328.9M
3WELLINGTON MANAGEMENT GROUP LLP6,089,516$131.5M
4STATE STREET CORP5,412,901$116.9M
5SUVRETTA CAPITAL MANAGEMENT, LLC5,030,993$108.7M
6VANGUARD PORTFOLIO MANAGEMENT LLC4,272,056$92.3M
7VANGUARD CAPITAL MANAGEMENT LLC3,856,725$83.3M
8Woodline Partners LP3,777,798$81.6M
9MARSHALL WACE, LLP3,761,437$81.2M
10Siren, L.L.C.3,007,077$65.0M
11GEODE CAPITAL MANAGEMENT, LLC2,252,367$48.7M
12Fisher Asset Management, LLC2,190,404$47.3M
13SAMLYN CAPITAL, LLC1,908,412$41.2M
14BNP PARIBAS ASSET MANAGEMENT Holding S.A.1,654,754$35.7M
15DIMENSIONAL FUND ADVISORS LP1,426,223$30.8M